*Dear Editor*,

BH3-mimetic drugs that antagonize Bcl-2 family prosurvival proteins are effective against some cancers, particularly those with abnormally high expression of the prosurvival protein target.^[@bib1]^ Despite the recent success of BH3-mimetics targeting Bcl-2, Bcl-x~L~ and Bcl-w, mechanism-based cell killing *in vivo* by targeting other important prosurvival proteins such as Mcl-1 or Bfl-1 has yet to be demonstrated. In the absence of small molecules targeting these prosurvival proteins, BH3-domain peptides, the prototypes for this class of drug, are useful because their binding specificity profile can be manipulated.^[@bib2],\ [@bib3]^ Such peptides have been applied in *in vitro* studies to validate the targeting of particular prosurvival proteins in certain tumor types.^[@bib4],\ [@bib5]^ However, *in vivo* applications require technically challenging chemical modifications of peptides, and while mouse xenograft models of virally-infected BH3 domain-expressing tumor cells can be used, this does not allow evaluation of effects of the ligand on normal tissues.

Here we have generated transgenic mice in which peptide-based BH3 ligands can be inducibly expressed to evaluate their effects *in vivo* and provide proof-of-principle for similar-acting drugs. To achieve this we adapted a previously described strategy allowing FLP-recombinase-mediated insertion of an expression cassette at an frt 'landing pad\' at the type I collagen (*Col1a1*) locus in mouse embryonic stem cells.^[@bib6]^ The cassette comprises sequences encoding a BH3-domain protein under control of a tetracycline (tet)-regulated element (TRE) promoter. To develop a system that is broadly applicable to BH3 domains with different specificities, we employed the Bim~S~ BH3-only protein as a scaffold in which BH3 domains with different specificities could replace the native BH3 sequence ([Figure 1a](#fig1){ref-type="fig"}). Bim~S~ is an intrinsically unstructured protein that tolerates extensive mutation of its BH3 sequence, and Bim~S~BH3 chimeras display the prosurvival protein specificity profile of the replacement BH3 domain.^[@bib7]^ In this study we focussed on the BH3 domain of Bad because it targets the prosurvival proteins Bcl-2, Bcl-x~L~ and Bcl-w.^[@bib7]^ Hence Bim~S~Bad expression should mimic the BH3-mimetics ABT-737 and ABT-263 that have been extensively studied *in vivo*.^[@bib1]^

We generated TRE-Bim~S~Bad transgenic mice and crossed them to mice expressing the rtTA (tet-on) transactivator under the control of the cytomegalovirus (CMV) promoter, which provides high-level expression in many tissues including blood.^[@bib8]^ Bitransgenic mice were then treated with doxycycline (Dox) to induce Bim~S~Bad expression ([Figure 1a](#fig1){ref-type="fig"}). Western blot analysis verified Dox-inducible transgene expression in white blood cells of Bim~S~Bad; CMV-rtTA bitransgenic mice ([Figure 1b](#fig1){ref-type="fig"}). As ABT-737/263 induces thrombocytopenia in mice and humans due to antagonism of Bcl-x~L~, we measured platelet levels as a biomarker for functional expression of the ligand.^[@bib1]^ Notably, blood cell analysis of these mice revealed a significant reduction (\~65% decrease) in platelet counts ([Figure 1c and d](#fig1){ref-type="fig"}), a degree of thrombocytopenia comparable with that seen in patients administered with ABT-263.^[@bib9]^ Importantly, platelet counts rebounded to normal levels following removal of Dox for 7 days ([Figure 1d](#fig1){ref-type="fig"}), illustrating the reversibility of the system. We also generated an additional transgenic mouse strain allowing inducible expression of a Bim~S~Bad construct possessing a BH3 sequence mutation (Bim~S~Bad^mut^; [Figure 1a](#fig1){ref-type="fig"}) that decreases its affinity for Bcl-x~L~ by \>40-fold (K~D~ 8.5 nM *versus* \<0.2 nM as measured by surface plasmon resonance). Induction of Bim~S~Bad^mut^ expression ([Figure 1b](#fig1){ref-type="fig"}) did not alter blood cell or platelet counts ([Figure 1d](#fig1){ref-type="fig"}), indicating that the thrombocytopenia observed in Bim~S~Bad mice is due to Bcl-x~L~ inhibition. These data provide the first evidence that BH3-only proteins can be inducibly expressed in a mouse model, effectively mimicking at least one functional consequence (reduced platelet counts) seen in mice and humans treated with BH3-mimetic drugs of similar specificity. We envisage multiple applications for similarly engineered mice. For example, tet-regulated expression of different Bim~S~ variants in mice could reveal toxicities associated with neutralization of their prosurvival protein targets (individually or in combination), and tissue-specific effects could be addressed by crossing onto mice where rtTA expression is driven by different promoters. Moreover, mice crossed to different tumor-prone models could provide *in vivo* evidence for the tumor-killing efficacy associated with different BH3 specificities not yet available through small molecule drugs, and extended to studies on combination therapies with existing drugs.
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![Expression of Bim~S~Bad reduces platelet levels in mice. (**a**) Schematic of the CMV-rtTA and TRE-Bim~S~Bad transgenes. Upon Dox treatment of bitransgenic mice, the rtTA (tet-on) protein transactivates the TRE promoter to drive expression of N-terminally FLAG tagged Bim~S~Bad. Targeting vectors were generated by cloning MluI-flanked FLAG-Bim~S~Bad/Bim~S~Bad^mut^ PCR amplicons into the MluI site of a modified version of the pgkATGfrt vector^[@bib6]^ in which the TRE promoter has been replaced with TREtight. BH3 domain numbering refers to the amino acid residue position within the respective Bim~S~ or Bad protein sequences. The BadBH3 residue in red (F121) was mutated to alanine in the Bim~S~Bad^mut^ mice. Targeted ES cell clones were injected into C57Bl/6 blastocysts and chimeras crossed to C57Bl/6 female mice. All mouse colonies were maintained by C57Bl/6 backcrossing. (**b**) Western blot of white blood cells isolated from TRE-Bim~S~Bad/Bim~S~Bad^mut^; CMV-rtTA bitransgenic mice or wild-type or Bim~S~Bad/Bim~S~Bad^mut^ single transgenic control mice following 7 days of Dox food (600 mg/kg). Blood (100 *μ*l) was cleared of red blood cells by 10-fold dilution in red cell lysis buffer for 5 min followed by centrifugation. The white blood cell-containing pellet was then resuspended in lysis buffer (20 mM Tris pH 7.4, 135 mM NaCl, 1.5 mM MgCl~2~, 1 mM EGTA, 1% Triton X100 and 10% glycerol) for 1 h on ice, followed by centrifugation. The supernatant was then analyzed by Western blot probed with an anti-FLAG antibody and reprobed with anti-β-actin as loading control. \* Indicates a non-specific band (**c**) Blood cell parameters after Dox treatment of bitransgenic and control animals for 7 days. \*\*\*\**P*\<0.0001 (*t*-test) compared with littermate controls (**d**) Platelet levels in TRE-Bim~S~Bad bitransgenic mice treated with Dox for 7 days rebound to normal levels after 7 days without Dox treatment. No changes in platelet levels were observed in Bim~S~Bad^mut^ mice following Dox treatment](cddis201554f1){#fig1}
